ClinicalTrials.gg
TerminatedNCT04430543Updated Oct 2, 2026Results posted

Neural and Behavioral Effects of Cognitive Bias Modification (CBM)

An interventional study of Cognitive Bias Modification and Sham Training in Alcohol Drinking, sponsored by Boston University Charles River Campus. Terminated at 1 site in United States. Open to participants aged 18 Years to 34 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionAlcohol Drinking(the registry's first term)UnverifiedIs this wrong?Alcohol Drinking is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Study terminated early due to COVID -19 and subsequent inability to run subjects at the facility.

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2019, registered Jun 2020).
Updated Oct 2, 2026Now TerminatedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 34 Years
Sex
All
01

Study summary

This study seeks to better understand mechanisms of behavior change for heavy drinkers who are interested in changing their drinking. The study will examine the effects of CBM as an adjunctive treatment on neurocognitive processes related to alcohol use in a sample of heavy/at-risk drinkers using functional magnetic resonance imaging (fMRI). The primary aim of this project is to examine the effects of CBM on neurocognitive approach tendencies and control processes, among heavy/at-risk drinkers interested in changing their alcohol use. As a secondary aim, this project will investigate associations between neural and cognitive changes and changes in alcohol use to better understand how CBM might lead to successful changes in drinking behavior. Either CBM (treatment group) or sham computer task (control group) will be paired with a motivational web-based intervention for alcohol use. Brain activity will be measures twice via fMRI--pre-treatment and 1-week post-treatment. The experimental tasks completed in the fMRI scans include 2 alcohol cue reactivity (CR) tasks--one standard and one in which participants are told to either inhibit (INHIBIT) or engage in (INDULGE) their reaction to images of alcohol and neutral beverages. Follow-up drinking behavior will be measured also at 1-week and online via 1- and 6-month follow-ups. Brain activity at baseline and follow-up will be measured in pre-defined regions of interest including amygdala, NAcc, mPFC, and dlPFC. It is hypothesized that the CBM group will exhibit changes in approach biases as exhibited by reductions in brain activity in the amygdala, NAcc, mPFC in response to alcohol cues in both CR tasks (alcohol CR, INDULGE CR, and INHIBIT CR) compared to sham. In addition, those in the CBM group will show increased dlPFC brain activity during alcohol CR and INHIBIT trials of the cued-CR task as evidence strengthened control abilities in response to alcohol cues. Finally, as a secondary hypothesis, those in the CBM group will show greater reductions in drinking and craving at follow-up.

Read the detailed description

Forty heavy/at-risk drinkers (ages 18-34) who report an interest in changing their drinking behavior will be recruited for this proposed project. "Interest" will be operationalized as an affirmative answer on an item adapted (for past-month) from the CAGE questionnaire: "In the past month, have you felt you should cut down or stop drinking?" (Mayfield, McLeod, \& Hall, 1974). Heavy/at-risk drinking will be defined in terms of consumption (7+/14+ drinks per week and/or 3+/4+ drinks on one occasion over the past week for women and men, respectively; USDHHS, 2005) and score on the Alcohol Use Disorders Identification Test (AUDIT score of 8-19; Babor, Higgins-Biddle, Saunders, \& Monteiro, 2001). A score between 8-19 on the AUDIT is indicative of heavy use while scores 20 and above are indicative of a more severe alcohol use disorder (i.e., "dependence", DSM-IV; APA, 2013; APA, 2000). Participants will be recruited through online advertisements on Craigslist, social media websites, and "Quickie Job Board" listings on student websites as well as via flyers in community and student health centers. Upon responding to advertisements participants will be administered a phone screen or complete online screening survey to determine study eligibility.

If eligible, baseline assessments will be administered at an in person appointment, including self-report assessments about alcohol use, drug use, consequences, and alcohol craving. Participants will complete a baseline fMRI scan, which involves administration of two versions of an alcohol cue reactivity (CR) task. Both CR tasks administered in the scanner will consist of a block design. The first alcohol CR task consists of two types of blocks-1) alcohol and 2) neutral beverage (i.e., soft drinks, juice, water). Subjects will be presented with 40 alcohol images and 40 neutral beverage images, respectively. The second task, the cued-CR task, involves 3 blocks utilizing the same images as the alcohol-CR task. Subjects will receive instructions regarding their reaction to the photos-1) INHIBIT CR (alcohol images), 2) INHIBIT NEUTRAL (neutral beverage images), and 3) INDULGE CR (alcohol images). More specifically, participants will be given the instruction to imagine each image is available to them and to either inhibit their natural reaction to the images presented (alcohol in one block, neutral beverages in another block) or think about the possibility of consuming, in this moment, each (alcohol-containing) beverage shown. This task was inspired by fMRI studies using CR tasks and cognitive restraint strategies to inhibit cravings for food and/or alcohol (Naqvi et al., 2015; Yokum \& Stice, 2013). For both tasks, each image will be presented for 4 seconds followed by a 2 second inter-image interval. Participants will be asked to rate their level of craving after each block for the first task only. Following this baseline scan, participants will complete a brief web-based intervention for alcohol use, Rethinking Drinking: Alcohol and Your Health (NIAAA, 2015), and will subsequently be randomized to either cognitive bias modification (CBM) or sham training. They will complete the first session of either CBM or sham training after randomization as well as an additional 4 CBM/sham sessions at home (via web) over one week following baseline. Participants will return to the lab one-week following their baseline appointment. At follow-up assessment, participants will complete all baseline assessment measures in addition to a second fMRI session consisting of the same CR tasks. Finally, participants will be emailed a link to a web-based survey at 1- and 6-months following baseline to assess drinking behavior. Data analysis will employ region of interest (ROI) analysis. Predefined ROIs include the bilateral amygdala, nucleus accumbens (NAcc), and dorsolateral and medial prefrontal cortex (dlPFC and mPFC). Anatomical ROIs will be generated using the Wake Forest University (WFU) Pickatlas automatic anatomical labeling tool (Maldjian, Laurienti, Kraft, \& Burdette, 2003) available for SPM. The analytic plan for testing study hypotheses are as follows: Primary Aim 1-For the alcohol CR task, two within subject contrasts will be calculated-1] alcohol CR > neutral CR pre-CBM/sham and 2] (alcohol CR > neutral CR) pre-CBM/sham - (alcohol CR > neutral CR) post-CBM/sham-in pre-defined ROIs. Primary Aim 2-as with the alcohol CR task, the within subject contrasts will be 1] INDULGE CR > INHIBIT CR pre-CBM/sham and 2] (INDULGE CR > INHIBIT CR) pre-CBM/sham - (INDULGE CR > INHIBIT CR) post-CBM/sham. Similar within subject contrasts will be explored for INHIBIT CR and INHIBIT NEUTRAL CR as a control. T-tests will be used to compare within subject contrasts for each task as well as to compare between-group contrasts (i.e., alcohol CR and INHIBIT CR pre-and post- CBM/sham). Secondary Aim: Correlations will be run to determine whether BL BOLD activity in each ROI significantly correlate with behavioral measures for both BL and 1-week follow-up. For significant correlations, pre- and post-CBM/sham difference scores will be calculated for behavioral measures and then correlated with significant BOLD contrasts representing change in neural activity.

02

Conditions studied

  • Alcohol Drinking

Browse trials for

Keywords

  • motivation
  • alcohol-related disorders
  • self-control
03

In context

Alcohol Drinking Unverified

703 studies on the registry are indexed under Alcohol Drinking; 132 are open to participants now.

This study's enrollment of 10 is below the median of 125 across 609 interventional studies indexed under Alcohol Drinking.

Browse Alcohol Drinking studies →

Lead sponsor

Boston University Charles River Campus is the lead sponsor of 160 studies on the registry; 34 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Compared within Alcohol Drinking, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 34 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • current hazardous drinking (score of 8+ on USAUDIT-C)
  • interest in changing drinking
  • English-speaking
  • able to provide

Exclusion criteria

Exclusion Criteria:

  • Score of 25+ on USAUDIT
  • current or past treatment for alcohol or drug use
  • lifetime diagnosis of other substance use disorder
  • self-reported weekly or more other drug use as indicated on the NIDA-modified Alcohol, Smoking, and Substance Involvement Screening Test
  • history of head injury or loss of consciousness
  • lifetime diagnosis of bipolar disorder, psychotic symptomatology, organic mental disorder, seizure disorder, or central nervous system disease
  • pregnancy
  • current use of psychotropic medication
  • history of delirium tremens and/or seizures as a result of alcohol withdrawal
  • to fMRI (claustrophobia, pregnancy, metal, pacemaker, etc.).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    CBM Group

    This group will receive Cognitive Bias Modification training

    Behavioral: Cognitive Bias Modification

  • Sham comparator
    Control Group

    This group will receive Sham (control) training

    Behavioral: Sham Training

Interventions

  • BehavioralCognitive Bias Modification

    CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when "pulled" and will get smaller as if moving away when "pushed". CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%).

  • BehavioralSham Training

    Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when "pulled" and will get smaller as if moving away when "pushed". Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)

06

What researchers measure

Primary outcomes

  1. Blood Oxygen Level Dependent (BOLD) Signal Change

    Blood oxygen level dependent (BOLD) signal change in ROIs \[amygdala, nucleus accumbent (NAcc), medial prefrontal cortex (mPFC), dorsolateral prefrontal cortex (dlPFC) during alcohol cue-reactivity decreased signal indicates better outcomes for amygdala, NAcc, and mPFC; increased signal indicates better outcomes for dlPFC

    Time frame: 1-week

  2. BOLD Signal Change in ROIs (Amygdala, NAcc, mPFC, dlPFC) During INHIBIT Cue-reactivity

    Decreased signal indicates better outcomes for amygdala, NAcc, and mPFC; increased signal indicates better outcomes for dlPFC

    Time frame: 1-week

  3. BOLD Signal Change in ROIs (Amygdala, NAcc, mPFC) During INDULGE Cue-reactivity

    Decreased BOLD signal change in ROIs indicates better outcomes for amygdala, NAcc, and mPFC

    Time frame: 1-week

Secondary outcomes

  1. Drinking Behavior

    Daily Drinking Questionnaire quantity item "most drinks on one occasion"; range 0-31; higher score = more drinking/worse outcome

    Time frame: 1-week

  2. Drinking Behavior

    Daily Drinking Questionnaire quantity item "most drinks on one occasion"; range 0-31; higher score = more drinking/worse outcome

    Time frame: 1-month

  3. Drinking Behavior

    Daily Drinking Questionnaire quantity item "most drinks on one occasion"; range 0-31; higher score = more drinking/worse outcome

    Time frame: 6-months

  4. Alcohol Craving

    Score on Desire for Alcohol Questionnaire; range (average of all 14 items) = -3 - 3; higher scores reflect higher desire for alcohol (worse outcome)

    Time frame: 1-week

  5. Alcohol Craving

    Score on Desire for Alcohol Questionnaire; range (average of all 14 items) = -3 - 3; ; higher scores reflect higher desire for alcohol (worse outcome)

    Time frame: 1-month

07

Results

Posted Oct 2, 2026
Limitations and caveats
Data collection was halted and ultimately discontinued due to restrictions due to the COVID-19 pandemic on in-person data collection starting March 2020. These restrictions impeded the researchers from collecting full data. None of the BOLD outcome measures (primary outcome measures 1-3) could be collected given the COVID-19 in person restrictions. Only incomplete data from 8 subjects was collected up to 1-month follow-up. No participants completed 6-month follow-up assessment.

Participant flow

Individuals were recruited for this study via student job board postings, Facebook advertisements, and advertisements in student health clinics. Recruitment spanned from 8/21/2019 to 2/25/2020. Recruitment and enrollment were halted as of 3/17/2020 due to COVID-19 and associated shutting down of universities and research space.

Participant flow — Overall Study
MilestoneCBM GroupControl Group
Started44
Completed00
Not completed44
Withdrew: Study discontinued due to covid-1944

Outcome measures

PrimaryBlood Oxygen Level Dependent (BOLD) Signal Change

Blood oxygen level dependent (BOLD) signal change in ROIs \[amygdala, nucleus accumbent (NAcc), medial prefrontal cortex (mPFC), dorsolateral prefrontal cortex (dlPFC) during alcohol cue-reactivity decreased signal indicates better outcomes for amygdala, NAcc, and mPFC; increased signal indicates better outcomes for dlPFC

Time frame:
1-week

No measurements were reported for this outcome.

PrimaryBOLD Signal Change in ROIs (Amygdala, NAcc, mPFC, dlPFC) During INHIBIT Cue-reactivity

Decreased signal indicates better outcomes for amygdala, NAcc, and mPFC; increased signal indicates better outcomes for dlPFC

Time frame:
1-week

No measurements were reported for this outcome.

PrimaryBOLD Signal Change in ROIs (Amygdala, NAcc, mPFC) During INDULGE Cue-reactivity

Decreased BOLD signal change in ROIs indicates better outcomes for amygdala, NAcc, and mPFC

Time frame:
1-week

No measurements were reported for this outcome.

SecondaryDrinking Behavior

Daily Drinking Questionnaire quantity item "most drinks on one occasion"; range 0-31; higher score = more drinking/worse outcome

Time frame:
1-week
Reported as:
Mean · drinks/occassion
Drinking Behavior
drinks/occassionCBM GroupControl Group
Drinking Behavior8.67 ± 4.046.25 ± 1.71
SecondaryDrinking Behavior

Daily Drinking Questionnaire quantity item "most drinks on one occasion"; range 0-31; higher score = more drinking/worse outcome

Time frame:
1-month
Reported as:
Mean · drinks/occassion
Drinking Behavior
drinks/occassionCBM GroupControl Group
Drinking Behavior—6.25 ± 2.06
SecondaryDrinking Behavior

Daily Drinking Questionnaire quantity item "most drinks on one occasion"; range 0-31; higher score = more drinking/worse outcome

Time frame:
6-months

No measurements were reported for this outcome.

SecondaryAlcohol Craving

Score on Desire for Alcohol Questionnaire; range (average of all 14 items) = -3 - 3; higher scores reflect higher desire for alcohol (worse outcome)

Time frame:
1-week
Reported as:
Mean · score on a scale
Alcohol Craving
score on a scaleCBM GroupControl Group
Alcohol Craving-1.60 ± .27-1.73 ± .39
SecondaryAlcohol Craving

Score on Desire for Alcohol Questionnaire; range (average of all 14 items) = -3 - 3; ; higher scores reflect higher desire for alcohol (worse outcome)

Time frame:
1-month
Reported as:
Mean · score on a scale
Alcohol Craving
score on a scaleCBM GroupControl Group
Alcohol Craving—-1.55 ± .56

Adverse events

Collected over Adverse event data were collected over the course of 6 months for each participant.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CBM Group0/4 (0%)0/4 (0%)0/4 (0%)
Control Group0/4 (0%)0/4 (0%)0/4 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)CBM GroupControl GroupTotal
Mean22.75 ± 3.3022.0 ± 5.4822.38 ± 3.06
Sex: Female, Male
Sex: Female, Male(Participants)CBM GroupControl GroupTotal
Female022
Male426
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)CBM GroupControl GroupTotal
Count of participants——0
past month frequency of drinking
past month frequency of drinking(days/month)CBM GroupControl GroupTotal
Mean3.75 ± .53 ± 03.38 ± .52
Weekend drinking quantity
Weekend drinking quantity(drinks/day)CBM GroupControl GroupTotal
Mean5 ± 1.634.25 ± .54.63 ± 1.19
Greatest number of drinks consumed
Greatest number of drinks consumed(drinks/occassion)CBM GroupControl GroupTotal
Mean9 ± 4.247.25 ± 1.718.13 ± 3.14
Alcohol Craving
Alcohol Craving(score on scale)CBM GroupControl GroupTotal
Mean-2.0 ± .27-1.38 ± .24-1.69 ± .41
08

Study locations

1 site
  • Rajen Kilachand Center for Integrated Life Sciences and Engineering at Boston University
    Boston, Massachusetts 02215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Aug 2021, 24 months.

Results were first posted in Oct 2026, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2020
First posted
Jun 12, 2020
StartActual
Aug 21, 2019
Primary completionActual
Aug 31, 2021
CompletionActual
Aug 31, 2021
Results first posted
Oct 2, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Study terminated early due to COVID -19 and subsequent inability to run subjects at the facility.
changed Oct 2, 2026
Results
Results posted
posted Oct 2, 2026
Enrollment
11→10
Oct 2, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedBOLD signal changeSignal Change in ROIs (amygdalaAmygdala, NAcc, mPFC, dlPFC) during alcohol cueDuring INHIBIT Cue-reactivityTime frame: 1-week
  • EditedBOLD signal changeSignal Change in ROIs (amygdalaAmygdala, NAcc, mPFC, dlPFC) during INHIBIT cueDuring INDULGE Cue-reactivityTime frame: 1-week
  • ChangedBefore BOLD signal change in ROIs (amygdala, NAcc, mPFC) during INDULGE cue-reactivityNow Blood Oxygen Level Dependent (BOLD) Signal ChangeTime frame: 1-week
Oct 2, 2026
Secondary outcomes
1 removed, 2 description edited
What changed in the outcomes
  • RemovedAlcohol CravingTime frame: 6-months
  • DescriptionAlcohol Craving: how it is measured was reworded
  • DescriptionAlcohol Craving#2: how it is measured was reworded
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Completed→Terminated
    Why stopped Study terminated early due to COVID -19 and subsequent inability to run subjects at the facility.
    Results posted
    Enrollment 11→10
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedBOLD signal changeSignal Change in ROIs (amygdalaAmygdala, NAcc, mPFC, dlPFC) during alcohol cueDuring INHIBIT Cue-reactivityTime frame: 1-week
    • EditedBOLD signal changeSignal Change in ROIs (amygdalaAmygdala, NAcc, mPFC, dlPFC) during INHIBIT cueDuring INDULGE Cue-reactivityTime frame: 1-week
    • ChangedBefore BOLD signal change in ROIs (amygdala, NAcc, mPFC) during INDULGE cue-reactivityNow Blood Oxygen Level Dependent (BOLD) Signal ChangeTime frame: 1-week
    Secondary outcomes 1 removed, 2 description edited
    What changed in the outcomes
    • RemovedAlcohol CravingTime frame: 6-months
    • DescriptionAlcohol Craving: how it is measured was reworded
    • DescriptionAlcohol Craving#2: how it is measured was reworded
    + 5 other changes: verification date, responsible party, contact details, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04430543
Responsible party
Sponsor
First posted
Jun 12, 2020
Start date
Aug 21, 2019
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021
Results posted
Oct 2, 2026
Last update
Oct 2, 2026

Study contacts

Kelli Tahaney, M.A.
principal investigator · Boston University Charles River Campus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion